Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
per-serving dose: Some brands list 500mg on the front but require you to take 2-3 capsules to reach that amount
In 1994, after almost a decades absence from competition, he won the 56-mile Comrades Marathon, a punishing test of endurance across the hot hills of South Africa
Novel pro-GSH molecules as multi-functional antioxidants
Improved hydration retention : Enhanced moisture-binding leads to visibly plumper, less crepey skin, especially in dehydrated or mature complexions